Activators of Plasminogen

  • Alice K. Robison
  • Burton E. Sobel
Part of the NATO ASI Series book series (NSSA, volume 125)

Abstract

Fluidity of the blood without hemorrhage is maintained by the physiological equilibrium between the coagulation and fibrinolytic systems, each of which is comprised of intrinsic and extrinsic components. Activators of fibrinogen are compounds whose teleological function is the dissolution of fibrin clots which could potentially upset this hemostatic balance if left undisturbed.

Keywords

Placebo Toxicity Catheter Ischemia Citrate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Been, M., DeBono, D. P., Muir, A. L., Boulton, F. E., Hillis, W. S., and Hornung, R., 1985, Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921, Br. Heart J., 53: 253.PubMedCrossRefGoogle Scholar
  2. Bergmann, S. R., Fox, K. A. A., Ter-Pogossian, M. M., Sobel, B. E., and Collen, D., 1983, Clot-selective coronary thrombolysis with tissue-type plasminogen activator, Science, 220: 1181.PubMedCrossRefGoogle Scholar
  3. Brommer, E. J. P., 1984, The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards, Thromb. Res., 34: 109.PubMedCrossRefGoogle Scholar
  4. Browne, M. J., Dodd, I., Carey, J. E., Chapman, C. G., and Robinson, J. H., 1985, Increased yield of human tissue-type plasminogen activator obtained by means of recombinant DNA technology, Thromb. Haemostas., 54: 422.Google Scholar
  5. Collen, D., Topol, E. J., Tiefenbrunn, A. J., Gold, H. K., Weisfeldt, M. L., Sobel, B. E., Leinbach, R. C., Brinker, J. A., Ludbrook, P. A., Yasuda, I., Bulkley, B. H., Robison, A. K., Hutter, A. M., Jr., Bell, W. R., Spadaro, J. J., Jr., Khaw, B. A., and Grossbard, E. B., 1984, Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial, Circulation, 70: 1012.PubMedCrossRefGoogle Scholar
  6. Dupe, R. J., English, P. D., Smith, R. A. G., and Green, J., 1984, Acyl-enzymes as thrombolytic agents in dog models of venous thrombosis nad pulmonary embolism, Thromb. Haemostas., 51: 248.Google Scholar
  7. Dupe, R. J., Green, J., and Smith, R. A. G., 1985, Acylated derivatives of streptokinase-plasminogen activator complex as thrombolytic agents in a dog model of aged venous thrombosis, Thromb. Haemostas., 53: 56.Google Scholar
  8. European Cooperative Study Group, 1985, Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction, The Lancet, April 13.Google Scholar
  9. Fox, K. A. A., Robison, A. K., Knabb, R. M., Rosamond, T. L., Sobel, B. E., and Bergmann, S. R., 1985, Prevention of coronary thrombosis with subthrombolytic doses of tissue-type polasminogen activator, Circulation, 72: 1346.PubMedCrossRefGoogle Scholar
  10. Gold, H. K., Fallon, J. T., Yasuda, T., Leinback, R. C., Khaw, B. A., Newell, J. B., Guerrero, J. L., Vislousky, F. M., Hoyng, C. F., Grossbard, E., and Collen, D., 1984, Coronary thrombolysis with recombinant human tissue-type plasminogen activator, Circulation, 70: 700.PubMedCrossRefGoogle Scholar
  11. Hoffmann, J.J. M.L., Van Rey, F. J. W., and Bonnier, J. J. R. M., 1985, Systemic effects of BRL 26921 during thrombolytic threatment of acute myocardial infarction, Thromb. Res., 37: 567.PubMedCrossRefGoogle Scholar
  12. Kasper, W., Erbel, R., Meinertz, T., Drexler, M., Ruckel, A., Pop, T., Prellwitz, W., and Meyer, J. 1984, Intracoronary thrombolysis with an acylated streptokinase-plasminogen activator (BRL 26921) in patients iwth acute myocardial infarction, J. Am. Coll. Cardiol., 4: 357.PubMedCrossRefGoogle Scholar
  13. Marder, V. J., Rothbard, R. L., Fitzpatrick, P. G., and Francis, C. W., 1986, Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex, Ann. Int. Med., 104: 304.PubMedCrossRefGoogle Scholar
  14. Matsuo, O., Collen, D., and Verstraete, M., 1981, On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921), Thromb. Res., 24: 347.PubMedCrossRefGoogle Scholar
  15. Ny, T., Elgh, F., and Lund, B., 1984, The structure of the human tissue-type plasminogen activator gene: Correlation of intron and exon structures to functional and structural domains, Proc. Natl. Acad. Sci. USA, 81: 5355.PubMedCrossRefGoogle Scholar
  16. Pennica, D., Holmes, W. E., Kohr, W. J., Harkins, R. N., Vehar, G. A., Ward, C. A., Bennett, W. F., Yelverton, E., Seeburg, P. H., Heyneker, H. L., Goeddel, D. V., and Collen, D. 1983, Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli, Nature, 301, 214.CrossRefGoogle Scholar
  17. Rijken, D. C. and Collen, D., 1981, Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture, J. Biol. Chem., 256: 7035.PubMedGoogle Scholar
  18. Smith, R. A. G., Dupe, R. J., English, P. D., and Green, J., 1982, Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis, Thromb. Haemostas., 47: 269.Google Scholar
  19. Smith, R. A. G., Dupe, R. J., English, P. D., and Green, J., 1981, Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy, Nature, 290: 505.PubMedCrossRefGoogle Scholar
  20. Sobel, B. E., Fields, L. E., Robison, A. K., Fox, K. A. A., and Sarnoff, S. J., 1985, Coronary thrombolysis with facilitated absorption of intramuscularly injected tissue-type plasminogen activator, Proc. Natl. Acad. Sci. USA, 82: 4258.PubMedCrossRefGoogle Scholar
  21. TIMI Study Group, 1985, The thrombolysis in myocardial infarction (TIMI) trial, N. Engl. J. Med., 312: 932.Google Scholar
  22. Tiefenbrunn, A. J., Robison, A. K., Kurnik, P. B., Ludbrook, P. A., and Sobel, B. E., 1985, Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology, Circulation, 71: 110.PubMedCrossRefGoogle Scholar
  23. Van de Werf, F., Bergmann, S. R., Fox, K. A. A., de Geest, H., Hoyng, C. F., Sobel, B. E., and Collen, D., 1984, Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology, Circulation, 69: 605.PubMedCrossRefGoogle Scholar
  24. Van de Werf, F., Ludbrook, P. A., Bergmann, S. R., Tiefenbrunn, A. J., Fox, K. A. A., de Geest, H., Verstraete, M., Collen, D., and Sobel, B. E., 1984, Copronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction, N. Engl. J. Med., 310: 609.PubMedCrossRefGoogle Scholar
  25. Walker, I. D., Davidson, J. F., Rae, A. P., Hutton, I. and Lawrie, T. D. V., 1983, Acyl-streptokinase-plasminogen activator complex in acute myocardial infarction (AMI), Br. J. Haematol., 53: 344.Google Scholar
  26. Walker, I. D., Davidson, J. F., Rae, A. P., Hutton, I., and Lawrie, T. D. V., 1984, Acylated streptokinase — plasminogen complex in patients with acute myocardial infarction, Thromb. Haemostas., 51: 204.Google Scholar
  27. Zamarron, C., Lijnen, H. R., and Collen, D., 1984, Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro, Thromb. Res., 35: 335.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1986

Authors and Affiliations

  • Alice K. Robison
    • 1
  • Burton E. Sobel
    • 1
  1. 1.Cardiovascular DivisionWashington University School of MedicineSt. LouisUSA

Personalised recommendations